{"DataElement":{"publicId":"3930586","version":"2","preferredName":"Inherited Metabolic Disorder Classification Type","preferredDefinition":"A description of the inherited metabolic disorder classification.","longName":"3930551v1.0:3930554v1.1","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"3930551","version":"1","preferredName":"Inherited Metabolic Disorder Classification","preferredDefinition":"Transmitted through genes from parents to offspring. (genome.gov)_A congenital (due to inherited enzyme abnormality) or acquired (due to failure of a metabolic important organ) disorder resulting from an abnormal metabolic process._A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.","longName":"3930549v1.0:2321361v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"3930549","version":"1","preferredName":"Inherited Metabolic Disorder","preferredDefinition":"Transmitted through genes from parents to offspring. (genome.gov):A congenital (due to inherited enzyme abnormality) or acquired (due to failure of a metabolic important organ) disorder resulting from an abnormal metabolic process.","longName":"C28018:C3235","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Inherited","conceptCode":"C28018","definition":"Transmitted through genes from parents to offspring. (genome.gov)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Metabolic Disorder","conceptCode":"C3235","definition":"A congenital (due to inherited enzyme abnormality) or acquired (due to failure of a metabolic important organ) disorder resulting from an abnormal metabolic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9971614-94F6-B942-E040-BB89AD4335DE","latestVersionIndicator":"Yes","beginDate":"2013-10-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-25","modifiedBy":"ONEDATA","dateModified":"2013-10-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2321361","version":"1","preferredName":"Classification","preferredDefinition":"Classification; the grouping of things into classes or categories.","longName":"C25161","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Classification","conceptCode":"C25161","definition":"A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCF89106-20AF-2D93-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-29","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-07-29","modifiedBy":"ONEDATA","dateModified":"2005-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9971614-9504-B942-E040-BB89AD4335DE","latestVersionIndicator":"Yes","beginDate":"2013-10-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-25","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3930554","version":"1.1","preferredName":"Inherited Metabolic Disorder Type","preferredDefinition":"Transmitted through genes from parents to offspring. (genome.gov)_A congenital (due to inherited enzyme abnormality) or acquired (due to failure of a metabolic important organ) disorder resulting from an abnormal metabolic process._Something distinguishable as an identifiable class based on common qualities.","longName":"3930554v1.1","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Beta-glucuronidase deficiency (VII)","valueDescription":"Sly Syndrome","ValueMeaning":{"publicId":"3028420","version":"1","preferredName":"Sly Syndrome","longName":"3028420","preferredDefinition":"A rare autosomal recessive lysosomal storage disease caused by deficiency of the enzyme beta-glucuronidase. It is characterized by hepatosplenomegaly, skeletal deformities, enlarged head, and mental retardation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sly Syndrome","conceptCode":"C84903","definition":"A rare autosomal recessive lysosomal storage disease caused by deficiency of the enzyme beta-glucuronidase. It is characterized by hepatosplenomegaly, skeletal deformities, enlarged head, and mental retardation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8228AACA-FD23-E06A-E040-BB89AD437846","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"WHITES","dateCreated":"2010-03-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FEBA971A-D103-B3BB-E040-BB89AD4317CE","beginDate":"2007-10-03","endDate":null,"createdBy":"NYCHM","dateCreated":"2014-07-21","modifiedBy":"ONEDATA","dateModified":"2014-07-21","deletedIndicator":"No"},{"value":"Fucosidosis","valueDescription":"Fucosidosis","ValueMeaning":{"publicId":"3028419","version":"1","preferredName":"Fucosidosis","longName":"3028419","preferredDefinition":"An autosomal recessive lysosomal storage disease characterized by a defective alpha-L-fucosidase. It results in accumulation of fucose in the tissues. Signs and symptoms include psychomotor retardation, dysostosis multiplex, and neural disturbances.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fucosidosis","conceptCode":"C61274","definition":"An autosomal recessive lysosomal storage disease characterized by a defective alpha-L-fucosidase. It results in accumulation of fucose in the tissues. Signs and symptoms include psychomotor retardation, dysostosis multiplex, and neural disturbances.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8228AACA-FCFE-E06A-E040-BB89AD437846","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"WHITES","dateCreated":"2010-03-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FEBA8E02-3B5F-90DF-E040-BB89AD43378C","beginDate":"2007-10-03","endDate":null,"createdBy":"NYCHM","dateCreated":"2014-07-21","modifiedBy":"ONEDATA","dateModified":"2014-07-21","deletedIndicator":"No"},{"value":"Gaucher disease","valueDescription":"Gaucher Disease","ValueMeaning":{"publicId":"3028418","version":"1","preferredName":"Gaucher Disease","longName":"3028418","preferredDefinition":"An inherited lysosomal storage disease caused by deficiency of the enzyme glucocerebrosidase. It results in the accumulation of a fatty substance called glucocerebroside in mononuclear cells in the bone marrow, liver, spleen, brain, and kidneys. Signs and symptoms include hepatomegaly, splenomegaly, neurologic disorders, lymphadenopathy, skeletal disorders, anemia and thrombocytopenia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gaucher Disease","conceptCode":"C61268","definition":"An inherited lysosomal storage disease caused by deficiency of the enzyme glucocerebrosidase. It results in the accumulation of a fatty substance called glucocerebroside in mononuclear cells in the bone marrow, liver, spleen, brain, and kidneys. Signs and symptoms include hepatomegaly, splenomegaly, neurologic disorders, lymphadenopathy, skeletal disorders, anemia and thrombocytopenia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8228AACA-FCDB-E06A-E040-BB89AD437846","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"WHITES","dateCreated":"2010-03-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FEBA8E02-3B69-90DF-E040-BB89AD43378C","beginDate":"2007-10-03","endDate":null,"createdBy":"NYCHM","dateCreated":"2014-07-21","modifiedBy":"ONEDATA","dateModified":"2014-07-21","deletedIndicator":"No"},{"value":"Hunter syndrome (II)","valueDescription":"Hunter Syndrome","ValueMeaning":{"publicId":"3322769","version":"1","preferredName":"Hunter Syndrome","longName":"3322769","preferredDefinition":"An X-linked, inherited lysosomal storage disease caused by the deficiency of the enzyme iduronate sulfatase that is responsible for the degradation of mucopolysaccharides. It nearly always affects males and is characterized by the accumulation of mucopolysaccharides in various organs, resulting in mental dysfunction, enlarged abdomen, hearing loss, obstructive airway disease, heart disease, and hepatosplenomegaly","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hunter Syndrome","conceptCode":"C61260","definition":"An X-linked, inherited lysosomal storage disease caused by the deficiency of the enzyme iduronate sulfatase that is responsible for the degradation of mucopolysaccharides.  It nearly always affects males and is characterized by the accumulation of mucopolysaccharides in various organs, resulting in mental dysfunction, enlarged abdomen, hearing loss, obstructive airway disease, heart disease, and hepatosplenomegaly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3714D57-A937-7A8F-E040-BB89AD43536C","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FEBA8E02-3B73-90DF-E040-BB89AD43378C","beginDate":"2007-10-03","endDate":null,"createdBy":"NYCHM","dateCreated":"2014-07-21","modifiedBy":"ONEDATA","dateModified":"2014-07-21","deletedIndicator":"No"},{"value":"Hurler syndrome (IH)","valueDescription":"Hurler Syndrome","ValueMeaning":{"publicId":"3028416","version":"1","preferredName":"Hurler Syndrome","longName":"3028416","preferredDefinition":"An autosomal recessive inherited disorder of mucopolysaccharide metabolism. It is the most severe form of mucopolysaccharidosis type I. It is characterized by deficiency of the enzyme alpha-L-iduronidase resulting in the accumulation of mucopolysaccharides in the tissues.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hurler Syndrome","conceptCode":"C61261","definition":"An autosomal recessive inherited disorder of mucopolysaccharide metabolism. It is the most severe form of mucopolysaccharidosis type I. It is characterized by deficiency of the enzyme alpha-L-iduronidase resulting in the accumulation of mucopolysaccharides in the tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8228AACA-FC95-E06A-E040-BB89AD437846","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"WHITES","dateCreated":"2010-03-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FEBA8E02-3B7D-90DF-E040-BB89AD43378C","beginDate":"2007-10-03","endDate":null,"createdBy":"NYCHM","dateCreated":"2014-07-21","modifiedBy":"ONEDATA","dateModified":"2014-07-21","deletedIndicator":"No"},{"value":"I-cell disease","valueDescription":"I-Cell Disease","ValueMeaning":{"publicId":"3188499","version":"1","preferredName":"I-Cell Disease","longName":"3188499","preferredDefinition":"An inherited lysosomal storage disease characterized by the presence of dense intracytoplasmic inclusions in mesenchymal cells, especially fibroblasts. Signs and symptoms include developmental delay, psychomotor deterioration, and growth failure.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"I-Cell Disease","conceptCode":"C61270","definition":"An inherited lysosomal storage disease characterized by the presence of dense intracytoplasmic inclusions in mesenchymal cells, especially fibroblasts. Signs and symptoms include developmental delay, psychomotor deterioration, and growth failure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9B6858FA-72BE-8EA3-E040-BB89AD433118","latestVersionIndicator":"Yes","beginDate":"2011-02-03","endDate":null,"createdBy":"NYCHM","dateCreated":"2011-02-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FEBA8E02-3B87-90DF-E040-BB89AD43378C","beginDate":"2007-10-03","endDate":null,"createdBy":"NYCHM","dateCreated":"2014-07-21","modifiedBy":"ONEDATA","dateModified":"2014-07-21","deletedIndicator":"No"},{"value":"Inherited metabolic disorder, not otherwise specified","valueDescription":"Not Otherwise Specified Congenital Metabolic Disorder","ValueMeaning":{"publicId":"2685148","version":"1","preferredName":"Not Otherwise Specified Congenital Metabolic Disorder","longName":"2685148","preferredDefinition":"Not characterized in any other way.: Errors in metabolic processes resulting from inborn genetic mutations that are inherited or acquired in utero.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Congenital Metabolic Disorder","conceptCode":"C34816","definition":"A group of disorders present at birth that involve genetic defects leading to disturbances in carbohydrate, lipid, lysosomal storage or amino acid metabolism in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3B969676-73A4-1128-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FEBA8E02-3B91-90DF-E040-BB89AD43378C","beginDate":"2007-10-03","endDate":null,"createdBy":"NYCHM","dateCreated":"2014-07-21","modifiedBy":"ONEDATA","dateModified":"2014-07-21","deletedIndicator":"No"},{"value":"Metachromatic leukodystrophy (MLD)","valueDescription":"Metachromatic Leukodystrophy","ValueMeaning":{"publicId":"2593450","version":"1","preferredName":"Metachromatic Leukodystrophy","longName":"2593450","preferredDefinition":"An autosomal recessive inherited disorder characterized by abnormalities in the development of the myelin sheaths. It is caused by a deficiency of the enzyme arylsulfatase A. There are three forms of this disease: late infantile, juvenile, and adult. In the late infantile form symptoms include muscle weakness and rigidity, gait disturbances, developmental delays, and seizures. In the juvenile form symptoms include gait disturbances, mental deterioration and seizures. The adult form is characterized by psychotic symptoms and dementia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metachromatic Leukodystrophy","conceptCode":"C61251","definition":"An autosomal recessive inherited disorder characterized by abnormalities in the development of the myelin sheaths. It is caused by a deficiency of the enzyme arylsulfatase A. There are three forms of this disease: late infantile, juvenile, and adult. In the late infantile form symptoms include muscle weakness and rigidity, gait disturbances, developmental delays, and seizures. In the juvenile form symptoms include gait disturbances, mental deterioration and seizures. The adult form is characterized by psychotic symptoms and dementia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28BBABB0-0B0C-4B1B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FEBA8E02-3B9B-90DF-E040-BB89AD43378C","beginDate":"2007-10-03","endDate":null,"createdBy":"NYCHM","dateCreated":"2014-07-21","modifiedBy":"ONEDATA","dateModified":"2014-07-21","deletedIndicator":"No"},{"value":"Morquio (IV)","valueDescription":"Morquio Syndrome","ValueMeaning":{"publicId":"2593471","version":"1","preferredName":"Morquio Syndrome","longName":"2593471","preferredDefinition":"A rare autosomal recessive lysosomal storage disease characterized by abnormal skeletal developments, dwarfism, heart disorders, and central nervous system deficits.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Morquio Syndrome","conceptCode":"C61263","definition":"A rare autosomal recessive lysosomal storage disease characterized by abnormal skeletal developments, dwarfism, heart disorders, and central nervous system deficits.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28BBEE5A-A52B-56E1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FEBA8E02-3BA5-90DF-E040-BB89AD43378C","beginDate":"2007-10-03","endDate":null,"createdBy":"NYCHM","dateCreated":"2014-07-21","modifiedBy":"ONEDATA","dateModified":"2014-07-21","deletedIndicator":"No"},{"value":"Krabbe disease (globoid leukodystrophy)","valueDescription":"Krabbe Disease","ValueMeaning":{"publicId":"2593454","version":"1","preferredName":"Krabbe Disease","longName":"2593454","preferredDefinition":"A rare inherited neurodegenerative disorder that belongs to the group of leukodystrophies. It is characterized by myelin destruction, gliosis in the brain, and the presence of multinucleated globoid cells. Signs and symptoms include irritability, mental and motor developmental disturbances, muscle weakness, seizures, blindness, and deafness.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Krabbe Disease","conceptCode":"C61254","definition":"A rare inherited neurodegenerative disorder that belongs to the group of leukodystrophies. It is characterized by myelin destruction, gliosis in the brain, and the presence of multinucleated globoid cells. Signs and symptoms include irritability, mental and motor developmental disturbances, muscle weakness, seizures, blindness, and deafness.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28BBAC79-C5A9-4B39-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FEBA8E02-3BAF-90DF-E040-BB89AD43378C","beginDate":"2007-10-03","endDate":null,"createdBy":"NYCHM","dateCreated":"2014-07-21","modifiedBy":"ONEDATA","dateModified":"2014-07-21","deletedIndicator":"No"},{"value":"Lesch-Nyhan (HGPRT deficiency)","valueDescription":"Lesch-Nyhan Syndrome","ValueMeaning":{"publicId":"3028414","version":"1","preferredName":"Lesch-Nyhan Syndrome","longName":"3028414","preferredDefinition":"An X-linked inherited syndrome caused by mutations in the gene that encodes the enzyme hypoxanthine-guanine phosphoribosyltransferase, resulting in accumulation of uric acid in the body. It affects males and is characterized by neurologic defects, moderate mental retardation, muscle hypotonia, and a tendency for self-mutilation (self-biting of lips, tongue, and fingertips).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lesch-Nyhan Syndrome","conceptCode":"C61255","definition":"An X-linked inherited syndrome caused by mutations in the gene that encodes the enzyme hypoxanthine-guanine phosphoribosyltransferase, resulting in accumulation of uric acid in the body. It affects males and is characterized by neurologic defects, moderate mental retardation, muscle hypotonia, and a tendency for self-mutilation (self-biting of lips, tongue, and fingertips).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8228AACA-FC4F-E06A-E040-BB89AD437846","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"WHITES","dateCreated":"2010-03-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FEBA8E02-3BB9-90DF-E040-BB89AD43378C","beginDate":"2007-10-03","endDate":null,"createdBy":"NYCHM","dateCreated":"2014-07-21","modifiedBy":"ONEDATA","dateModified":"2014-07-21","deletedIndicator":"No"},{"value":"Mannosidosis","valueDescription":"Mannosidosis","ValueMeaning":{"publicId":"3323204","version":"1","preferredName":"Mannosidosis","longName":"3323204","preferredDefinition":"A rare autosomal recessive lysosomal storage disease characterized by a deficient activity of the enzymes alpha-D-mannosidase or beta-mannosidase.  Clincal signs and symptoms include hepatomegaly, splenomegaly, hearing loss, mental retardation, skeletal abnormalities, and recurrent respiratory infections.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mannosidosis","conceptCode":"C61275","definition":"A rare autosomal recessive lysosomal storage disease characterized by a deficient activity of the enzymes alpha-D-mannosidase or beta-mannosidase. Clinical signs and symptoms include hepatomegaly, splenomegaly, hearing loss, mental retardation, skeletal abnormalities, and recurrent respiratory infections.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3724AB2-B07C-5E8E-E040-BB89AD433884","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FEBA8E02-3BC3-90DF-E040-BB89AD43378C","beginDate":"2007-10-03","endDate":null,"createdBy":"NYCHM","dateCreated":"2014-07-21","modifiedBy":"ONEDATA","dateModified":"2014-07-21","deletedIndicator":"No"},{"value":"Maroteaux-Lamy (VI)","valueDescription":"Maroteaux-Lamy Syndrome","ValueMeaning":{"publicId":"3028412","version":"1","preferredName":"Maroteaux-Lamy Syndrome","longName":"3028412","preferredDefinition":"A rare autosomal recessive lysosomal storage disease caused by deficiency of the enzyme N-acetylgalactosamine-4-sulfatase. It is characterized by organomegaly, short stature, joint stiffness, otitis media, and respiratory illnesses.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Maroteaux-Lamy Syndrome","conceptCode":"C61264","definition":"A rare autosomal recessive lysosomal storage disease caused by deficiency of the enzyme N-acetylgalactosamine-4-sulfatase. It is characterized by organomegaly, short stature, joint stiffness, otitis media, and respiratory illnesses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8228AACA-FC07-E06A-E040-BB89AD437846","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"WHITES","dateCreated":"2010-03-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FEBA8E02-3BCD-90DF-E040-BB89AD43378C","beginDate":"2007-10-03","endDate":null,"createdBy":"NYCHM","dateCreated":"2014-07-21","modifiedBy":"ONEDATA","dateModified":"2014-07-21","deletedIndicator":"No"},{"value":"Mucolipidoses, not otherwise specified","valueDescription":"Not Otherwise Specified Mucolipidosis","ValueMeaning":{"publicId":"3930581","version":"1","preferredName":"Not Otherwise Specified Mucolipidosis","longName":"3930581","preferredDefinition":"Not characterized in any other way.: A group of inherited lysosomal storage diseases characterized by accumulation of lipids and carbohydrates in the tissues, resulting in mental disabilities and skeletal malformations.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Mucolipidosis","conceptCode":"C61267","definition":"A group of inherited lysosomal storage diseases characterized by accumulation of lipids and carbohydrates in the tissues, resulting in mental disabilities and skeletal malformations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9988CEE-C55E-330D-E040-BB89AD433F76","latestVersionIndicator":"Yes","beginDate":"2013-10-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FEBA8E02-3BD7-90DF-E040-BB89AD43378C","beginDate":"2007-10-03","endDate":null,"createdBy":"NYCHM","dateCreated":"2014-07-21","modifiedBy":"ONEDATA","dateModified":"2014-07-21","deletedIndicator":"No"},{"value":"Osteopetrosis (malignant infantile osteopetrosis)","valueDescription":"Osteopetrosis","ValueMeaning":{"publicId":"2593448","version":"1","preferredName":"Osteopetrosis","longName":"2593448","preferredDefinition":"Excessive formation of dense trabecular bone leading to pathological fractures, OSTEITIS, SPLENOMEGALY with infarct, ANEMIA, and extramedullary hemopoiesis (HEMATOPOIESIS, EXTRAMEDULLARY).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Osteopetrosis","conceptCode":"C26840","definition":"A rare genetic disorder inherited in an autosomal dominant, autosomal recessive, or X-linked recessive pattern. In the majority of cases it is caused by mutations in the CLCN7, TCIRG1, or IKBKG genes. It is characterized by excessive bone formation due to the failure of osteoclasts to resorb bone. It manifests with deformities, fractures, hepatosplenomegaly, anemia, and extramedullary hematopoiesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28BBAB4E-68BC-4B19-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FEBA8E02-3BE1-90DF-E040-BB89AD43378C","beginDate":"2007-10-03","endDate":null,"createdBy":"NYCHM","dateCreated":"2014-07-21","modifiedBy":"ONEDATA","dateModified":"2014-07-21","deletedIndicator":"No"},{"value":"Mucopolysaccharidosis (V)","valueDescription":"Mucopolysaccharidosis","ValueMeaning":{"publicId":"3323207","version":"1","preferredName":"Mucopolysaccharidosis","longName":"3323207","preferredDefinition":"A group of autosomal recessive or X-linked inherited lysosomal storage disorders affecting the metabolism of mucopolysaccharides, resulting in the accumulation of mucopolysaccharides in the body. Signs and symptoms include organomegaly, mental retardation, abnormal skeletal development, heart disorders, hearing loss, and central nervous system deficiencies.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mucopolysaccharidosis","conceptCode":"C61259","definition":"A group of autosomal recessive or X-linked inherited lysosomal storage disorders affecting the metabolism of mucopolysaccharides, resulting in the accumulation of mucopolysaccharides in the body. Signs and symptoms include organomegaly, intellectual disabilities, abnormal skeletal development, heart disorders, hearing loss, and central nervous system deficiencies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3724AB2-B113-5E8E-E040-BB89AD433884","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FEBA8E02-3BEB-90DF-E040-BB89AD43378C","beginDate":"2007-10-03","endDate":null,"createdBy":"NYCHM","dateCreated":"2014-07-21","modifiedBy":"ONEDATA","dateModified":"2014-07-21","deletedIndicator":"No"},{"value":"Mucopolysaccharidosis, not otherwise specified","valueDescription":"Not Otherwise Specified Mucopolysaccharidosis","ValueMeaning":{"publicId":"3377615","version":"1","preferredName":"Not Otherwise Specified Mucopolysaccharidosis","longName":"3377615","preferredDefinition":"Not characterized in any other way.: A group of autosomal recessive or X-linked inherited lysosomal storage disorders affecting the metabolism of mucopolysaccharides, resulting in the accumulation of mucopolysaccharides in the body. Signs and symptoms include organomegaly, mental retardation, abnormal skeletal development, heart disorders, hearing loss, and central nervous system deficiencies.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Mucopolysaccharidosis","conceptCode":"C61259","definition":"A group of autosomal recessive or X-linked inherited lysosomal storage disorders affecting the metabolism of mucopolysaccharides, resulting in the accumulation of mucopolysaccharides in the body. Signs and symptoms include organomegaly, intellectual disabilities, abnormal skeletal development, heart disorders, hearing loss, and central nervous system deficiencies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8EE9528-25CC-ECE1-E040-BB89AD4354FD","latestVersionIndicator":"Yes","beginDate":"2012-02-14","endDate":null,"createdBy":"NYCHM","dateCreated":"2012-02-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FEBA8E02-3BF5-90DF-E040-BB89AD43378C","beginDate":"2007-10-03","endDate":null,"createdBy":"NYCHM","dateCreated":"2014-07-21","modifiedBy":"ONEDATA","dateModified":"2014-07-21","deletedIndicator":"No"},{"value":"Scheie syndrome (IS)","valueDescription":"Scheie Syndrome","ValueMeaning":{"publicId":"2582069","version":"1","preferredName":"Scheie Syndrome","longName":"2582069","preferredDefinition":"An autosomal recessive disorder representing the milder form of mucopolysaccharidosis type I. It is characterized by deficiency of the enzyme alpha-L-iduronidase. Signs and symptoms include broad mouth with full lips, cloudy cornea which may lead to blindness, stiff joints, and hirsutism.\r\n","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Scheie Syndrome","conceptCode":"C61265","definition":"An autosomal recessive disorder representing the milder form of mucopolysaccharidosis type I. It is characterized by deficiency of the enzyme alpha-L-iduronidase. Signs and symptoms include broad mouth with full lips, cloudy cornea which may lead to blindness, stiff joints, and hirsutism.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0DA2-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-21","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-11-21","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FEBA8E02-3BFF-90DF-E040-BB89AD43378C","beginDate":"2007-10-03","endDate":null,"createdBy":"NYCHM","dateCreated":"2014-07-21","modifiedBy":"ONEDATA","dateModified":"2014-07-21","deletedIndicator":"No"},{"value":"Niemann-Pick disease","valueDescription":"Niemann-Pick Disease","ValueMeaning":{"publicId":"3028411","version":"1","preferredName":"Niemann-Pick Disease","longName":"3028411","preferredDefinition":"An autosomal recessive inherited lysosomal storage disease characterized by deficiency of sphingomyelinase. It results in the accumulation of sphingomyelin in the liver, spleen, brain, lungs, and bone marrow. Signs and symptoms include hepatosplenomegaly, pancytopenia, ataxia, dystonia, and dementia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Niemann-Pick Disease","conceptCode":"C61269","definition":"An autosomal recessive inherited lysosomal storage disease characterized by deficiency of sphingomyelinase. It results in the accumulation of sphingomyelin in the liver, spleen, brain, lungs, and bone marrow. Signs and symptoms include hepatosplenomegaly, pancytopenia, ataxia, dystonia, and dementia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8228AACA-FBBC-E06A-E040-BB89AD437846","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"WHITES","dateCreated":"2010-03-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FEBA8E02-3C09-90DF-E040-BB89AD43378C","beginDate":"2007-10-03","endDate":null,"createdBy":"NYCHM","dateCreated":"2014-07-21","modifiedBy":"ONEDATA","dateModified":"2014-07-21","deletedIndicator":"No"},{"value":"Other inherited metabolic disorder","valueDescription":"Other Congenital Metabolic Disorder","ValueMeaning":{"publicId":"2685149","version":"1","preferredName":"Other Congenital Metabolic Disorder","longName":"2685149","preferredDefinition":"Not otherwise specified.: Errors in metabolic processes resulting from inborn genetic mutations that are inherited or acquired in utero.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Congenital Metabolic Disorder","conceptCode":"C34816","definition":"A group of disorders present at birth that involve genetic defects leading to disturbances in carbohydrate, lipid, lysosomal storage or amino acid metabolism in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3B969676-73CC-1128-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FEBA8E02-3C13-90DF-E040-BB89AD43378C","beginDate":"2007-10-03","endDate":null,"createdBy":"NYCHM","dateCreated":"2014-07-21","modifiedBy":"ONEDATA","dateModified":"2014-07-21","deletedIndicator":"No"},{"value":"Polysaccharide hydrolase abnormality, not otherwise specified","valueDescription":"Polysaccharide hydrolase abnormalities, NOS","ValueMeaning":{"publicId":"2685150","version":"1","preferredName":"Polysaccharide hydrolase abnormalities, NOS","longName":"2685150v1.00","preferredDefinition":"Not characterized in any other way._An enzyme that hydrolyzes the breakdown of a polysaccharide to simple sugars._A condition that differs from the usual physical or mental state.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Polysaccharide Hydrolase","conceptCode":"C99387","definition":"An enzyme that hydrolyzes the breakdown of a polysaccharide to simple sugars.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Abnormality","conceptCode":"C9440","definition":"A condition that differs from the usual physical or mental state.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3B969676-741E-1128-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-03","modifiedBy":"KUMMEROA","dateModified":"2024-01-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FEBA8E02-3C1D-90DF-E040-BB89AD43378C","beginDate":"2007-10-03","endDate":null,"createdBy":"NYCHM","dateCreated":"2014-07-21","modifiedBy":"ONEDATA","dateModified":"2014-07-21","deletedIndicator":"No"},{"value":"Sanfilippo (III)","valueDescription":"Sanfilippo Syndrome","ValueMeaning":{"publicId":"3326328","version":"1","preferredName":"Sanfilippo Syndrome","longName":"3326328","preferredDefinition":"A rare autosomal recessive lysosomal storage disease affecting the metabolism of mucopolysaccharides.  Signs and symptoms include behavioral changes, sleep disorders, mental developmental delays, and seizures.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sanfilippo Syndrome","conceptCode":"C61262","definition":"A rare autosomal recessive lysosomal storage disease affecting the metabolism of mucopolysaccharides. Signs and symptoms include behavioral changes, sleep disorders, mental developmental delays, and seizures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3862B52-B5D5-375A-E040-BB89AD436460","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FEBA8E02-3C27-90DF-E040-BB89AD43378C","beginDate":"2007-10-03","endDate":null,"createdBy":"NYCHM","dateCreated":"2014-07-21","modifiedBy":"ONEDATA","dateModified":"2014-07-21","deletedIndicator":"No"},{"value":"Wolman disease","valueDescription":"Wolman Disease","ValueMeaning":{"publicId":"3028409","version":"1","preferredName":"Wolman Disease","longName":"3028409","preferredDefinition":"A very rare, autosomal recessive inherited lysosomal storage disease caused by mutations in the LIPA gene. Signs and symptoms appear in infancy and include developmental delay, vomiting, abdominal distention, hepatosplenomegaly, jaundice, anemia, steatorrhea, and calcification of the adrenal glands.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Wolman Disease","conceptCode":"C61271","definition":"A very rare, autosomal recessive inherited lysosomal storage disease caused by mutations in the LIPA gene. Signs and symptoms appear in infancy and include developmental delay, vomiting, abdominal distention, hepatosplenomegaly, jaundice, anemia, steatorrhea, and calcification of the adrenal glands.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8228AACA-FAFB-E06A-E040-BB89AD437846","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"WHITES","dateCreated":"2010-03-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FEBA8E02-3C31-90DF-E040-BB89AD43378C","beginDate":"2007-10-03","endDate":null,"createdBy":"NYCHM","dateCreated":"2014-07-21","modifiedBy":"ONEDATA","dateModified":"2014-07-21","deletedIndicator":"No"},{"value":"Adrenoleukodystrophy (ALD)","valueDescription":"Adrenoleukodystrophy","ValueMeaning":{"publicId":"2593452","version":"1","preferredName":"Adrenoleukodystrophy","longName":"2593452","preferredDefinition":"A rare metabolic disorder characterized by damage of the myelin sheaths in the nervous system and degeneration of the adrenal glands. It leads to progressive neurologic disorders, adrenal insufficiency and death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adrenoleukodystrophy","conceptCode":"C61252","definition":"A rare metabolic disorder characterized by damage of the myelin sheaths in the nervous system and degeneration of the adrenal glands. It leads to progressive neurologic disorders, adrenal insufficiency and death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28BBAC12-A50B-4B21-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FEBA8E02-3C3B-90DF-E040-BB89AD43378C","beginDate":"2007-10-03","endDate":null,"createdBy":"NYCHM","dateCreated":"2014-07-21","modifiedBy":"ONEDATA","dateModified":"2014-07-21","deletedIndicator":"No"},{"value":"Glucose storage disease","valueDescription":"glucose storage disease","ValueMeaning":{"publicId":"2579872","version":"1","preferredName":"glucose storage disease","longName":"2579872v1.00","preferredDefinition":"An inherited metabolic disorder characterized either by defects in glycogen synthesis or defects in the breaking down of glycogen. It results either in the creation of abnormal forms of glycogen or accumulation of glycogen in the tissues.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glycogen Storage Disease","conceptCode":"C61272","definition":"An inherited metabolic disorder characterized either by defects in glycogen synthesis or defects in the breaking down of glycogen. It results either in the creation of abnormal forms of glycogen or accumulation of glycogen in the tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-050D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-16","modifiedBy":"KUMMEROA","dateModified":"2023-08-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FEBA8E02-3C45-90DF-E040-BB89AD43378C","beginDate":"2007-10-03","endDate":null,"createdBy":"NYCHM","dateCreated":"2014-07-21","modifiedBy":"ONEDATA","dateModified":"2014-07-21","deletedIndicator":"No"},{"value":"Aspartyl glucosaminidase","valueDescription":"Aspartylglycosaminuria","ValueMeaning":{"publicId":"3028421","version":"1","preferredName":"Aspartylglycosaminuria","longName":"3028421","preferredDefinition":"A rare autosomal recessive lysosomal disorder characterized by deficiency of N-aspartyl-beta-glucosaminidase. It is characterized by developmental delays during childhood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aspartylglycosaminuria","conceptCode":"C61273","definition":"A rare autosomal recessive lysosomal disorder characterized by deficiency of N-aspartyl-beta-glucosaminidase. It is characterized by developmental delays during childhood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8228AACA-FD46-E06A-E040-BB89AD437846","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"WHITES","dateCreated":"2010-03-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FEBA8E02-3C4F-90DF-E040-BB89AD43378C","beginDate":"2007-10-03","endDate":null,"createdBy":"NYCHM","dateCreated":"2014-07-21","modifiedBy":"ONEDATA","dateModified":"2014-07-21","deletedIndicator":"No"},{"value":"Neuronal ceroid lipofuscinosis (Batten disease)","valueDescription":"Batten Disease","ValueMeaning":{"publicId":"3377616","version":"1","preferredName":"Batten Disease","longName":"3377616","preferredDefinition":"A rare, often fatal, inherited neurodegenerative disorder characterized by the accumulation of lipopigments in the body. It is manifested in childhood. Signs and symptoms include progressive vision loss, progressive motor skills deterioration, mental impairment, and seizures.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neuronal Ceroid Lipofuscinosis Type 3","conceptCode":"C61258","definition":"A condition associated with mutation(s) in the CLN3 gene, encoding battenin. The condition is one of a group of genetically heterogeneous neurodegenerative disorders, characterized by accumulation of intracellular lipopigments.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8EE9528-2602-ECE1-E040-BB89AD4354FD","latestVersionIndicator":"Yes","beginDate":"2012-02-14","endDate":null,"createdBy":"NYCHM","dateCreated":"2012-02-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FEBA8E02-3C59-90DF-E040-BB89AD43378C","beginDate":"2007-10-03","endDate":null,"createdBy":"NYCHM","dateCreated":"2014-07-21","modifiedBy":"ONEDATA","dateModified":"2014-07-21","deletedIndicator":"No"},{"value":"Hereditary diffuse leukoencephalopathy with spheroids (HDLS)","valueDescription":"Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia","ValueMeaning":{"publicId":"7685355","version":"1","preferredName":"Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia","longName":"7685355","preferredDefinition":"A rapidly progressive neurodegenerative disorder, caused by mutations in the colony-stimulating factor 1 receptor (CSF1R) gene, that presents in adulthood with a variety of neuropsychiatric and motor disturbances. Hallmark features include diffuse myelin loss and axonal destruction, neuroaxonal spheroids, and pigmented macrophages and other glia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia","conceptCode":"C153289","definition":"A rapidly progressive neurodegenerative disorder, caused by mutations in the colony-stimulating factor 1 receptor (CSF1R) gene, that presents in adulthood with a variety of neuropsychiatric and motor disturbances. Hallmark features include diffuse myelin loss and axonal destruction, neuroaxonal spheroids, and pigmented macrophages and other glia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C46F9B82-5EE8-14D5-E053-4EBD850A99AD","latestVersionIndicator":"Yes","beginDate":"2021-06-10","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-06-10","modifiedBy":"ONEDATA","dateModified":"2021-06-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DDA8A9AD-4127-2DEA-E053-4EBD850A55FF","beginDate":"2022-04-27","endDate":null,"createdBy":"MALUMK","dateCreated":"2022-04-27","modifiedBy":"ONEDATA","dateModified":"2022-04-27","deletedIndicator":"No"},{"value":"Cerebral adrenoleukodystrophy (CALD)","valueDescription":null,"ValueMeaning":{"publicId":"14333416","version":"1","preferredName":"Cerebral Adrenoleukodystrophy","longName":"14333416v1.00","preferredDefinition":"A subtype of adrenoleukodystrophy (ALD) occurring in approximately 40 percent of boys with ALD, primarily affecting the cerebrum, resulting in rapidly declining neurocognitive function and in most patients, premature death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cerebral Adrenoleukodystrophy","conceptCode":"C142852","definition":"A subtype of adrenoleukodystrophy (ALD) occurring in approximately 40 percent of boys with ALD, primarily affecting the cerebrum, resulting in rapidly declining neurocognitive function and in most patients, premature death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"028053B8-3A24-0F5A-E063-731AD00A0594","latestVersionIndicator":"Yes","beginDate":"2023-08-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-08-09","modifiedBy":"KUMMEROA","dateModified":"2023-08-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"028053B8-3A25-0F5A-E063-731AD00A0594","beginDate":"2023-08-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-08-09","modifiedBy":"KUMMEROA","dateModified":"2023-08-09","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3930553","version":"1","preferredName":"Inherited Metabolic Disorder Type","preferredDefinition":"Transmitted through genes from parents to offspring. (genome.gov):A congenital (due to inherited enzyme abnormality) or acquired (due to failure of a metabolic important organ) disorder resulting from an abnormal metabolic process.:Something distinguishable as an identifiable class based on common qualities.","longName":"C28018:C3235:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Inherited","conceptCode":"C28018","definition":"Transmitted through genes from parents to offspring. (genome.gov)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Metabolic Disorder","conceptCode":"C3235","definition":"A congenital (due to inherited enzyme abnormality) or acquired (due to failure of a metabolic important organ) disorder resulting from an abnormal metabolic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E997B635-C26B-3C6F-E040-BB89AD437D7F","latestVersionIndicator":"Yes","beginDate":"2013-10-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-25","modifiedBy":"ONEDATA","dateModified":"2013-10-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FEBA8E02-3B3E-90DF-E040-BB89AD43378C","latestVersionIndicator":"Yes","beginDate":"2014-07-21","endDate":null,"createdBy":"NYCHM","dateCreated":"2014-07-21","modifiedBy":"KUMMEROA","dateModified":"2023-08-09","changeDescription":".PV added for 2402r7. 04/27/2022 KMM","administrativeNotes":"2023.8.9 PV added per ticket request CADSR0002719. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685478","version":"1","longName":"Testing Set – Moderately Different","context":"NCIP"}]}],"AlternateNames":[{"name":"PreTed_prime_dis_hct_inheri_disorder_metabo_class","type":"NMDP_FN","context":"NHLBI"},{"name":"CPRE_ICT_inh_disord_metab_cls","type":"NMDP_FN","context":"NHLBI"},{"name":"TDIS_IDM_inh_disord_metab_clss","type":"NMDP_FN","context":"NHLBI"},{"name":"PerformedDiagnosis:value","type":"HCT_BRIDG_5","context":"NHLBI"},{"name":"TDIS_IDM_inh_disord_metab_clas","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What was the classification o","type":"Preferred Question Text","description":"What was the classification of the inherited metabolic disorders?","url":null,"context":"NHLBI"},{"name":"Specify inherited disorders of metabolism classification","type":"Alternate Question Text","description":"Specify inherited disorders of metabolism classification","url":null,"context":"NHLBI"},{"name":"Specify inherited disorders of metabolism classification","type":"Application Standard Question Text","description":"Specify inherited disorders of metabolism classification","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FEBA971A-D11A-B3BB-E040-BB89AD4317CE","latestVersionIndicator":"Yes","beginDate":"2014-07-21","endDate":null,"createdBy":"NYCHM","dateCreated":"2014-07-21","modifiedBy":"ZHWENDY","dateModified":"2022-05-26","changeDescription":". Added human readable def. System generated def displayed as alt def. No version needed. AK 11/17/14; Added HCT_BRIDG5 alternate name - RR 2018-12-23","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}